Literature DB >> 16103896

An association study of 43 SNPs in 16 candidate genes with atorvastatin response.

J F Thompson1, M Man, K J Johnson, L S Wood, M E Lira, D B Lloyd, P Banerjee, P M Milos, S P Myrand, J Paulauskis, M A Milad, W J Sasiela.   

Abstract

Variation in individual response to statin therapy has been widely studied for a potential genetic component. Multiple genes have been identified as potential modulators of statin response, but few study findings have replicated. To further examine these associations, 2735 individuals on statin therapy, half on atorvastatin and the other half divided among fluvastatin, lovastatin, pravastatin and simvastatin were genotyped for 43 SNPs in 16 genes that have been implicated in statin response. Associations with low-density lipoprotein cholesterol (LDL-C) lowering, total cholesterol lowering, HDL-C elevation and triglyceride lowering were examined. The only significant associations with LDL-C lowering were found with apoE2 in which carriers of the rare allele who took atorvastatin lowered their LDL-C by 3.5% more than those homozygous for the common allele and with rs2032582 (S893A in ABCB1) in which the two groups of homozygotes differed by 3% in LDL-C lowering. These genetic effects were smaller than those observed with the demographic variables of age and gender. The magnitude of all the differences found is sufficiently small that genetic data from these genes should not influence clinical decisions on statin administration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103896     DOI: 10.1038/sj.tpj.6500328

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  57 in total

Review 1.  Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights.

Authors:  Ricardo Stein; Filipe Ferrari; Fernando Scolari
Journal:  Curr Cardiol Rep       Date:  2019-06-21       Impact factor: 2.931

Review 2.  Pharmacogenetics of response to statins.

Authors:  Issam Zineh
Journal:  Curr Atheroscler Rep       Date:  2007-09       Impact factor: 5.113

Review 3.  Genetics and personalized medicine--a role in statin therapy?

Authors:  Jaideep Patel; Thura Abd; Roger S Blumenthal; Khurram Nasir; H Robert Superko
Journal:  Curr Atheroscler Rep       Date:  2014-01       Impact factor: 5.113

Review 4.  Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.

Authors:  Kari T Kivistö; Mikko Niemi
Journal:  Pharm Res       Date:  2006-12-20       Impact factor: 4.200

5.  Regulation of apoAI processing by procollagen C-proteinase enhancer-2 and bone morphogenetic protein-1.

Authors:  Jian Zhu; Joseph Gardner; Clive R Pullinger; John P Kane; John F Thompson; Omar L Francone
Journal:  J Lipid Res       Date:  2009-02-23       Impact factor: 5.922

6.  [Pharmacogenomic Biomarkers for the Prediction of Statin Efficacy and Safety].

Authors:  Damiano Baldassarre; Mauro Amato; Beatrice Frigerio; Gualtiero Columbo; Philip F Binkley; Saurabh R Pandey; Adam M Suhy; Katherine Hartmann; Joseph P Kitzmiller
Journal:  G Ital Arterioscler       Date:  2013-11

7.  Non-synonymous polymorphisms in the human SLCO1B1 gene: an in vitro analysis of SNP c.1929A>C.

Authors:  Annick Seithel; Kathrin Klein; Ulrich M Zanger; Martin F Fromm; Jörg König
Journal:  Mol Genet Genomics       Date:  2007-11-08       Impact factor: 3.291

8.  Pitavastatin: finding its place in therapy.

Authors:  Leiv Ose
Journal:  Ther Adv Chronic Dis       Date:  2011-03       Impact factor: 5.091

9.  PharmGKB very important pharmacogene: SLCO1B1.

Authors:  Connie Oshiro; Lara Mangravite; Teri Klein; Russ Altman
Journal:  Pharmacogenet Genomics       Date:  2010-03       Impact factor: 2.089

10.  PharmGKB: very important pharmacogene--HMGCR.

Authors:  Marisa Wong Medina; Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-02       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.